Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Sandra Cohen, Nadia Bambace, Imran Ahmad, Jean Roy, Xiaoying Tang, Mei-Jie Zhang, Linda J Burns, Frédéric Barabé, Léa Bernard, Jean-Sébastien Delisle, Thomas Kiss, Silvy Lachance, Denis-Claude Roy, Olivier Veilleux, Guy Sauvageau
Cord blood (CB) transplantation is hampered by low cell dose and high non-relapse mortality (NRM). A phase I-II trial of UM171-expanded CB transplants demonstrated safety and favourable preliminary efficacy. The aim of the current analysis was to retrospectively compare results of the phase I-II trial to those after unmanipulated CB and matched unrelated donor (MUD) transplants. Data from recipients of CB and MUD transplants were obtained from the Center for International Blood and Marrow Transplant Research (CIBMTR) database...
July 19, 2023: Blood Advances
#22
JOURNAL ARTICLE
Christina Cho, Sean Devlin, Molly Maloy, Mary M Horowitz, Brent Logan, J Douglas Rizzo, Sergio A Giralt, Miguel-Angel Perales
The Web-based One Year Survival Outcomes Calculator developed by the Center for International Blood and Marrow Transplant Research (CIBMTR) applies large-scale registry data to generate individualized estimates of overall survival (OS) probability 1 year after first allogeneic hematopoietic cell transplant (HCT) and can therefore provide a data-driven foundation for personalized patient counseling. We assessed the calibration of the CIBMTR One Year Survival Outcomes Calculator when applied to retrospective data among adult recipients of first allogeneic HCT for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS) with peripheral blood stem cell transplant (PBSCT) from a 7/8- or 8/8-matched donor from 2000 through 2015 at a single center...
July 8, 2023: Bone Marrow Transplantation
#23
JOURNAL ARTICLE
Muhammad Bilal Abid, Noel Estrada-Merly, Mei-Jie Zhang, Karen Chen, David Allan, Christopher Bredeson, Mitchell Sabloff, Guru Subramanian Guru Murthy, Talha Badar, Shahrukh Hashmi, Mahmoud Aljurf, Mark R Litzow, Partow Kebriaei, Christopher S Hourigan, Wael Saber
INTRODUCTION: Allogeneic hematopoietic cell transplant (alloHCT) provides cure for older patients with acute myeloid leukemia (AML); however, disease relapse remains a major concern. Based on recent data suggesting that younger donor age confers the greatest benefit among matched unrelated donors (MUD), we attempted to answer a practical question: which donor type provides the best outcomes when an older patient with AML has a matched sibling donor (MSD, also older) vs the best MUD? METHODS: This retrospective cohort registry study accessed data from Center for International Blood and Marrow Transplant Research database (CIBMTR) in patients with AML 50 years or older undergoing alloHCT from older MSD (aged≥50) or younger MUD (aged≤35) between 2011 and 2018...
July 3, 2023: Transplantation and cellular therapy
#24
JOURNAL ARTICLE
Akshay Sharma, Brent Logan, Noel Estrada-Merly, Leslie E Lehmann, Hemalatha G Rangarajan, Jaime M Preussler, Jesse D Troy, Luke P Akard, Neel S Bhatt, Tony H Truong, William A Wood, Christopher Strouse, Mark Juckett, Nandita Khera, Douglas Rizzo, Wael Saber
BACKGROUND: The Center for International Blood and Marrow Transplant Research (CIBMTR) reports the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) at United States transplant centers (TC) annually through its Center-Specific Survival Analysis (CSA). The CSA compares the actual 1-year overall survival (OS) and predicted 1-year OS rate after alloHCT at each TC, which is then reported as 0 (OS as expected), -1 (OS worse than expected), or +1 (OS better than expected)...
May 21, 2023: Transplantation and cellular therapy
#25
JOURNAL ARTICLE
Roni Tamari, Donal P McLornan, Kwang Woo Ahn, Noel Estrada-Merly, Juan Carlos Hernandez-Boluda, Sergio A Giralt, Jeanne M Palmer, Robert Peter Gale, Zachariah DeFilipp, David Marks, Marjolein W M van der Poel, Leo F Verdonck, Minoo Battiwalla, Miguel A Díaz, Vikas Gupta, Haris Ali, Mark R Litzow, Hillard M Lazarus, Usama Gergis, Asad Bashey, Jane L Liesveld, Shahrukh Hashmi, Jeffrey J Pu, Amer Beitinjaneh, Christopher N Bredeson, David A Rizzieri, Bipin N Savani, Muhammad Bilal Abid, Siddhartha Ganguly, Vaibhav Agrawal, Vera Ulrike, Baldeep Wirk, Tania Jain, Corey S Cutler, Mahmoud Aljurf, Tamila Kindwall-Keller, Mohamed A Kharfan-Dabaja, Gerhard C Hildebrandt, Attaphol Pawarode, Melhem M Solh, Jean A Yared, Michael R Grunwald, Sunita Nathan, Taiga Nishihori, Sachiko Seo, Bart L Scott, Ryotaro Nakamura, Betul Oran, Tomasz Czerw, Ibrahim Yakoub-Agha, Wael Saber
To develop a prognostic model for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) for myelofibrosis (MF). We examined 623 patients undergoing allo-HCT between 2000 - 2016 in the USA (CIBMTR cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients transplanted in Europe (EBMT cohort) (n = 623). Age above 50 (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98 -1.96), and HLA matched unrelated donor (HR, 1...
May 3, 2023: Blood Advances
#26
JOURNAL ARTICLE
Yi-Bin Chen
No abstract text is available yet for this article.
April 2023: Clinical Advances in Hematology & Oncology: H&O
#27
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 2023: Clinical Advances in Hematology & Oncology: H&O
#28
JOURNAL ARTICLE
Steven M Devine, Stephanie Bo-Subait, Michelle Kuxhausen, Stephen R Spellman, Caitrin Bupp, Kwang Woo Ahn, Heather E Stefanski, Jeffery J Auletta, Brent R Logan, Bronwen E Shaw
At the onset of the COVID-19 pandemic, the National Marrow Donor Program mandated the cryopreservation of hematopoietic cell grafts from volunteer unrelated donors due to numerous patient and donor safety concerns and logistical hurdles. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) outcomes database, we report the impact of cryopreservation on overall survival (OS) and other outcomes within one year following hematopoietic cell transplantation (HCT). We analyzed 1,543 recipients of cryopreserved allografts receiving HCT at US centers during the first 6-months of the pandemic and compared them to 2,499 recipients of fresh allografts during the same 6-month period in 2019...
April 10, 2023: Blood Advances
#29
JOURNAL ARTICLE
Tristan E Knight, Kwang Woo Ahn, Kyle M Hebert, Rasha Atshan, Donna A Wall, Kanhatai Chiengthong, Seth J Rotz, Ellen Fraint, Hemalatha G Rangarajan, Jeffery J Auletta, Akshay Sharma, Carrie L Kitko, Hasan Hashem, Kirsten M Williams, Baldeep Wirk, Christopher C Dvorak, Kasiani C Myers, Michael A Pulsipher, Anne B Warwick, Nahal Rose Lalefar, Kirk R Schultz, Muna Qayed, Larisa Broglie, Mary Eapen, Gregory A Yanik
Consolidation with autologous hematopoietic stem cell transplantation (HSCT) has improved survival for patients with central nervous system tumors (CNSTs). The impact of the autologous graft CD34+ dose on patient outcomes is unknown. We wanted to analyze the relationship between CD34+ dose, total nucleated cell (TNC) dose, and clinical outcomes, including overall survival (OS), progression-free survival (PFS), relapse, non-relapse mortality (NRM), endothelial-injury complications (EIC), and time to neutrophil engraftment in children undergoing autologous HSCT for CNSTs...
June 2023: Transplantation and cellular therapy
#30
Michael Boyiadzis, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M Badawy, Minoo Battiwalla, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie I Brown, Paul Castillo, Jan Cerny, Edward A Copelan, Charles Craddock, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Christen L Ebens, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael R Grunwald, Shahrukh Hashmi, Gerhard C Hildebrandt, Madiha Iqbal, Omer Jamy, Mohamed A Kharfan-Dabaja, Nandita Khera, Hillard M Lazarus, Richard Lin, Dipenkumar Modi, Sunita Nathan, Taiga Nishihori, Sagar S Patel, Attaphol Pawarode, Wael Saber, Akshay Sharma, Melhem Solh, John L Wagner, Trent Wang, Kirsten M Williams, Lena E Winestone, Baldeep Wirk, Amer Zeidan, Christopher S Hourigan, Mark Litzow, Partow Kebriaei, Marcos de Lima, Kristin Page, Daniel J Weisdorf
No abstract text is available yet for this article.
March 22, 2023: Leukemia
#31
JOURNAL ARTICLE
Jeffery J Auletta, Jianqun Kou, Min Chen, Yung-Tsi Bolon, Larisa Broglie, Caitrin Bupp, Debra Christianson, Rachel N Cusatis, Steven M Devine, Mary Eapen, Kathryn E Flynn, Mehdi Hamadani, Mary Hengen, Stephanie J Lee, Amy Moskop, Kristin M Page, Marcelo C Pasquini, Waleska S Perez, Rachel Phelan, Marcie L Riches, J Douglas Rizzo, Wael Saber, Stephen R Spellman, Heather E Stefanski, Patricia Steinert, Eileen Tuschl, Rafeek Yusuf, Mei-Jie Zhang, Bronwen E Shaw
BACKGROUND: Use of human leukocyte antigen (HLA)-mismatched donors could enable more patients with ethnically diverse backgrounds to receive allogeneic hematopoietic cell transplantation (HCT) in the United States. However, real-world trends and outcomes following mismatched donor HCT for diverse patients remain largely undefined. OBJECTIVE: To determine whether mismatched donor platforms have increased access to allogeneic HCT for ethnically diverse patients, particularly through the application of novel graft-versus-host disease (GvHD) prophylaxis regimens, and if outcomes for diverse patients were comparable to those of non-Hispanic White patients...
March 14, 2023: Transplantation and cellular therapy
#32
JOURNAL ARTICLE
Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, Marcos DeLima, Shahrukh Hashmi, Mohamed A Kharfan-Dabaja, Navneet S Majhail, Rahul Banerjee, Ayman Saad, Gerhard C Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J Lekakis, Sagar S Patel, Hemant S Murthy, Yago Nieto, Christopher S Strouse, Sherif M Badawy, Samer Ai Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H Vesole, Cindy H Lee, Attaphol Pawarode, Usama Gergis, Kevin Charles Miller, Leona A Holmberg, Aimaz Afrough, Melhem M Solh, Pashna Munshi, Taiga Nishihori, Larry D Anderson, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H Qazilbash, Nina Shah, Shaji K Kumar, Saad Z Usmani
The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials employing auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM)...
February 24, 2023: Blood Advances
#33
Robert Gale, Wolfgang Hinterberger, Neal S Young, Andrew Gennery, Christopher Dvorak, Kyle Hebert, Michael Heim, Larisa Broglie, Mary Eapen
Background Aplastic anaemia has diverse aetiologies. Distinguishing between these is, in part, testable by analyzing results of haematopoietic cells transplants between genetically-identical twins one of whom has aplastic anaemia. Objective Describe outcomes of genetically-identical twin transplants for aplastic anaemia with and without pretransplant conditioning. Methods We interrogated data from an observational database of 59 consecutive recipients of genetically-identical twin transplants for aplastic anaemia reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) 2000-2019...
February 3, 2023: Research Square
#34
JOURNAL ARTICLE
Sarah Nikiforow, Matthew J Frigault, Noelle V Frey, Rebecca A Gardner, Krishna V Komanduri, Miguel-Angel Perales, Partow Kebriaei, Phyllis Irene Warkentin, Marcelo Pasquini, Joy Lynn Aho, Bruce L Levine, Helen E Heslop, Tracey L Hlucky, Karen Habucky, Mecide Gharibo, Madan Jagasia, Frederick L Locke
As the number and type of regulatory authority-approved cellular therapies grow, clinical treatment centers face a heavy burden of duplicative documentation around initial qualification, ongoing auditing, and reporting, with overlapping requirements from each manufacturer to ensure safe use of their specific product, which in the United States are stipulated under individual Food and Drug Administration (FDA) Biologic License Applications. The American Society for Transplantation and Cellular Therapy (ASTCT) convened the 80/20 Task Force to consider challenges and potential solutions to these issues...
April 2023: Transplantation and cellular therapy
#35
JOURNAL ARTICLE
Pedro Chorão, Juan Montoro, Aitana Balaguer-Roselló, Manuel Guerreiro, Marta Villalba, Ana Facal, Pilar Solves, Inés Gómez-Segui, Marcelo C Pasquini, Pablo Granados, Ana Bataller, Alberto Louro, Javier de la Rubia, Miguel A Sanz, Jaime Sanz
BACKGROUND: Bone marrow (BM) is the recommended stem cell source for hematopoietic stem cell transplantation (HSCT) from matched sibling donor (MSD) in severe aplastic anemia (SAA) for its superior survival and lower graft-versus-host disease (GVHD) outcomes compared to unmanipulated peripheral blood (PB). Nevertheless, studies comparing BM with ex vivo T-cell depleted (TCD) PB have not been reported so far. OBJECTIVES: The aim of this study was to compare the transplant outcomes of MSD-HSCT in SAA using PB (with partial ex vivo TCD targeted cell dose grafts) with those using unmanipulated BM...
January 19, 2023: Transplantation and cellular therapy
#36
JOURNAL ARTICLE
Idayat M Akinola, Rachel Cusatis, Marcelo C Pasquini, Bronwen E Shaw, Vamsi Bollu, Anand Dalal, Mimi Tesfayem, Kathryn E Flynn
BACKGROUND: Toxicities after chimeric antigen receptor T-cell therapy (CAR-T) are well known, yet the patient experience during and after CAR-T has not been well described outside of the trial setting. OBJECTIVE: We explored the patient experience after CAR-T to inform the patient-reported outcome measurement approach for the Center for International Blood and Marrow Transplant Research® (CIBMTR®). STUDY DESIGN: We recruited 1) adult patients diagnosed with a hematologic malignancy, 14 days to 6 months after receiving a commercial CAR T-cell product, who had agreed to be contacted by the CIBMTR, 2) caregivers of those patients, and 3) clinical experts in CAR-T...
January 9, 2023: Transplantation and cellular therapy
#37
JOURNAL ARTICLE
Guru Subramanian Guru Murthy, Brent R Logan, Stephanie Bo-Subait, Amer Beitinjaneh, Steven Devine, Nosha Farhadfar, Lohith Gowda, Shahrukh Hashmi, Hillard Lazarus, Sunita Nathan, Akshay Sharma, Jean A Yared, Heather E Stefanski, Michael A Pulsipher, Jack W Hsu, Galen E Switzer, Sandhya R Panch, Bronwen E Shaw
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). While many factors influence the outcomes of allo-HCT, the independent impact of donor-recipient ABO mismatching remains unclear. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified patients aged ≥18 years with AML or ALL who underwent allo-HCT between 2008 and 2018. Our objectives were to analyze the outcomes of allo-HCT based on the donor-recipient ABO status (match, minor mismatch, major mismatch, bidirectional mismatch)...
April 2023: American Journal of Hematology
#38
JOURNAL ARTICLE
Alberto Mussetti, Abraham S Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Hervé Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gülbas, Jose Diez-Martin, Steven G E Marsh, Sophie Paczesny, Shahinaz M Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R Spellman, Stephanie J Lee, Yung-Tsi Bolon, Anna Sureda
When using post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis for lymphoma patients, it is currently unknown whether a matched unrelated donor (MUD) or a haploidentical related donor is preferable if both are available. In this study we wanted to test whether using a haploidentical donor has the same results of a MUD. A total of 2140 adults (34% Center for International Blood and Marrow Transplant Research, 66% European Society for Blood and Marrow Transplantation registry) aged ≥18 years who received their first haploidentical hematopoietic cell transplantation (haplo-HCT) or MUD-HCT (8/8 match at HLA-loci A, B, C, and DRB1) for lymphoma using PTCy-based GVHD prophylaxis from 2010 to 2019 were retrospectively analyzed...
December 25, 2022: Transplantation and cellular therapy
#39
JOURNAL ARTICLE
Muthalagu Ramanathan, Soyoung Kim, Naya He, Min Chen, Peiman Hematti, Muhammad Bilal Abid, Seth J Rotz, Kirsten M Williams, Hillard M Lazarus, Baldeep Wirk, Dwight E Yin, Christopher G Kanakry, Miguel-Angel Perales, Roy F Chemaly, Christopher E Dandoy, Marcie Riches, Celalettin Ustun
Clostridioides difficile infection (CDI) is common after allogeneic hematopoietic cell transplantation (alloHCT). The determination of incidence, risk factors, and impact of CDI on alloHCT outcomes is an unmet need. The study examines all patients aged 2 years and older who received first alloHCT for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic syndrome (MDS) between 2013 and 2018 at US centers and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) data registry...
April 2023: Bone Marrow Transplantation
#40
JOURNAL ARTICLE
M L Schoettler, E Carreras, B Cho, C E Dandoy, V T Ho, S Jodele, I Moissev, I Sanchez-Ortega, A Srivastava, Y Atsuta, P Carpenter, J Koreth, N Kroger, P Ljungman, K Page, U Popat, B E Shaw, A Sureda, R Soiffer, S Vasu
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplantation (HCT) associated with significant morbidity and mortality. However, TA-TMA is a clinical diagnosis, and multiple criteria have been proposed without universal application. Although some patients have a self-resolving disease, others progress to multiorgan failure and/or death. Poor prognostic features also are not uniformly accepted. The lack of harmonization of diagnostic and prognostic markers has precluded multi-institutional studies to better understand incidence and outcomes...
March 2023: Transplantation and cellular therapy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
